Summary A method has been developed for measuring the drug sensitivity of human gliomas in short-term culture, using scintillation counting or autofluorography. Cell 
The growth of human glioma in cell culture offers a potentially valuable system for assaying the relative sensitivity of different tumours to antineoplastic drugs. The objective underlying the present experiments has been to develop an assay which will enable the comparison of drug sensitivities in a large number of different tumours and ultimately provide enough information on relative sensitivities to aid in the planning of chemotherapy.
Previous attempts at predictive drug testing (Limburg & Heckman, 1968 , Knock et al., 1974 , Nissen et al., 1978 , Salmon et al., 1978 have relied on relatively short drug exposures, usually considerably less than one cell cycle. The results with HeLa (Freshney et al., 1975) and with glioma (Morgan & Freshney, 1979) showed that observations of less than one cell cycle could often prove misleading. Hence prolonged drug exposure and recovery periods have been employed. An assay using microtifration plates has been selected for the present experiments because it provides a large number of replicates with low cell numbers and should be easy to automate. Isotopic labelling gives a rapid and objective assessment of cytotoxicity and has been found to be most suited to microtitration plates. The incorporation of labelled precursors into protein was selected as being least likely to be influenced directly by cytostatic drugs while still registering a reduction in the viability of the cell population. Previous results with this type of assay (Freshney, 1976 ) indicated a need to record the time course of the development of cytotoxicity. Maximum sensitivity was not expressed until after 4-5 cell population doublings, particularly with antimetabolites.
Although attempts to apply predictive drug testing to cells from many different types of solid tumour have often been prevented by the difficulty in obtaining pure replicating cultures of malignant cells, cell cultures from human glioma have been found to be made up predominantly of dividing aneuploid astrocyte-like cells, which are not overgrown by stromal fibroblasts.
The response of these cultures to a number of drugs is reported here in an attempt to compare the sensitivities of different cell lines in early passage culture. The selection of drugs was based both on clinical usage (e.g. procarbazine, CCNU and vincristine) and on previous indications of sensitivity in vitro (e.g. 5-fluorouracil, cytosine arabinoside and vinblastine). The assay is based on that of Freshney, et al., (1975) with the end point determined by scintillation counting or, where specified, scintillation autofluorography (Freshney & Morgan, 1978 , Thomas et al., 1979 After drug exposure, the monolayer was washed 3 x with fresh medium and the culture continued ("recovery period"). Throughout the recovery period the medium was replaced at least every 48 h. In time course experiments, a period of 3 h recovery wasg allowed for the equilibration of acid soluble pools and efflux of unbound drug when labelling was performed shortly after drug removal.
Sampling by scintillation counting At intervals during drug exposure and recovery the growth medium was replaced with medium containing 20 p Ci ml-' L-leucine-4, 5-[3H] (specific activity 10mCi M-1) and incubated for a further 4 h. The plates were washed, and cell protein, solubilized in IN NaOH, counted as previously described (Freshney et al., 1975 Ci M-1 before addition to medium) and adding scintillation fluid directly to the acid insoluble residues in the microtitration plate (Freshney & Morgan 1978) . The solvent was dried off by centrifugation and autofluorograms were prepared on Kodak RP Royal-X X-ray film at -70°C. The autofluorograms were analysed densitometrically on a Helena Autoscanner with a 7 x 2 mm slit and ID50 and ID90 values determined as above.
Cloning
Exponentially-growing cells were treated with drugs in 25cm2 flasks, the drugs being replaced daily for 3 days. The flasks were then trypsinised and by determining the number of cells in the control flask each cell suspension was diluted to give 50-200 cells ml-'.
The cells were plated out, either alone or on mitomycin-C treated (2 pg ml-1 overnight)
homologous feeder layers in 9 cm petri dishes (Nunclon). These were incubated for 2-3 weeks, fixed, stained and the colonies counted.
Results
Characterisation of cultures Twenty-four anaplastic astrocytomas, all of which grew well as monolayers, were selected for this study. Primary cultures of cells with long thin processes tended to form a network in subconfluent cultures, but gave way to polygonal or spindle-shaped cells after serial passage. Although karyotypes were not performed on all the lines used, examination of some, and of many similar lines derived in the same manner, showed considerable aneuploidy with modal chromosome numbers ranging from 40-46 chromosomes (Guner et al., 1977 , Freshney, 1980 . Recent evidence has shown that these cell cultures are capable of growth on confluent monolayers of normal contact-inhibited cells, while cells cultured from normal brain are not and that they have a higher labelling index with [3H] TdR at terminal cell density than cultures derived from normal brain .
Derivation of sensitivity measurements
Percentage inhibition curves displaying the effect of drug concentration on inhibition of [3H] leucine incorporation for 5-fluorouracil (5FU), cytosine arabinoside (Ara-C), mustine (MU) and vinblastine (VB) were used to derive ID50 values which were then plotted against time from addition of drug ( Figure 1 ). Increasing the exposure time reduced the ID50 and a further decrease was often observed during continued culture after removal of drug. In some cases, particularly with 5-FU, a plateau value was established between 6 and 8 days. Standard deviations of 4 replicate cultures exposed to 5-FU and Ara-C were 20% and 16% of the mean respectively, at the time of drug removal, and 28% and 43% respectively, at the end of the assay.
It has been assumed that an exposure period of 3 days allows most of the proliferating cells to pass through the cell cycle at least once in the presence of drug. As cycle times are known to vary within one tumour cell population and between cell lines from different tumours, some cells will not have completed a full cycle in the presence of drugs. However, this is such a small proportion that adapting the assay to suit such extremes would be technically unmanageable. Figure 2a) (Figure 2b ). Although the slope of the regression line was similar, there was greater scatter and this was not confined to any one cell line.
When the 5 cell lines were ranked in order of sensitivity by cloning and microtitration, the only major discrepancy arose with GMS and VM26 where cloning gave a lower ID50 than microtitration by 2 orders of magnitude. Any other alterations in ranking sequence were only due to minor differences in ID50. Ranking the cell lines by ID90 however, produced several discrepancies in keeping with the increased scatter observed in the regression plot.
Comparison of ID50 time courses in primary, secondary and tertiary cultures and in multiple culturesfrom the same biopsy Assays were performed on 2 cell lines (BRO and HNY) at different stages of culture (Figure 3) . Microtitration plates were set up (a) directly after removal of collagenase (primary culture), (b) after trypsinisation of the primary culture (secondary culture), and (c) after trypsinisation of the secondary culture (tertiary culture). These cultures were treated with 5-FU and MU and their viability determined by [3H] leucine incorporation and scintillation counting. Assays done on primary cultures showed marked oscillations in ID50 with time and did not conform to the time course predicted by the HeLa cell model (Freshney et al., 1975) . However, the secondary and tertiary cultures behaved in a more predictable fashion.
A comparison of replicate cultures and multiple cultures from the same biopsy also revealed that the greatest variability occurred during the early stages of an assay and the possibility exists that there is some degree of parasynchrony of the cell cycle induced by transfer prior to the commencement of Logio II
1) The ID50 in all cases fell rapidly, although not always continuously, between 24 and 72h. 2) A low ID50 at 24h was often, but not invariably, accompanied by a steep gradient in the rate of change of ID50.
3) A plateau of maximum sensitivity was reached with 5-FU at 72 h. 4) Vinblastine showed the greatest differences in sensitivity between lines suggesting a division into 2 groups, one insensitive and the other so sensitive that the ID50 drops below the minimum concentration. 5-FU sensitivities were similar by the end of the assay with the exception of one line that was apparently resistant. This line had a long doubling time of 132h. In most cases, however, a steep slope or low 3-day ID50 value did not correlate with a short doubling time. 5) Divergence in the curves for Ara-C suggested that there may have been differences in the rates at which maximum sensitivity was reached, but by the time maximum sensitivity was reached the differences in ID50 had diminished.
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Extrapolation might suggest further convergence had the assay continued for longer.
Extended series of comparative observations A more extensive series of observations was made with a different group of 20 tumours using the drugs procarbazine (PCB), CCNU, methyl-CCNU (Me-CCNU) and vincristine (VCR). These 4 drugs are amongst those most frequently used clinically for human glioma and are among the most effective. The results of this series are shown in Figure 5 (a-c) condensed to give the ID50 values after a 24-72h recovery period at the end of the log phase of growth, a point reached at different times by different cultures. Four observations can be made.
1) The sensitivity to PCB was low; no ID50 fell below the range of the predicted plasma level, although 3/13 (30%) fell within it. 2) All of the ID50 values for VCR fell below the predicted plasma concentration. Ten of 16 were closely grouped between 10-" M and 2 x l0-9 M, while the remaining 6 (38%) showed immediately after exposure to the drug (data not shown). This suggests that the effect of the drug on these cultures was transitory and resistance was readily achieved. Discussion The examination of replicate cultures suggests that the internal variation of the microtitration assay can be minimised by sampling 3-5 days after drug removal. With most cell lines this allows for at least one complete cell cycle in the absence of drugs, given that the average population doubling time for these cultures is about 36h and the cell cycle time of each line will vary around that figure. It was shown previously with HeLa cells (Freshney, 1976) that prolonged exposure to drugs and recovery were necessary to obtain a measurable and stable ID50 value for many drugs particularly those which are phase-specific. Present (see below) . There is no evidence for differences in the sensitivity of multiple cultures from different parts of the same biopsy. This does not mean that differences do not exist but that variant populations must represent a small component of the total population. The selection of a microtitration plate assay for this series of measurements was influenced by difficulties in obtaining reasonable plating efficiencies for a clonogenic assay. However, the selection of the appropriate CO2 tension (2%), use of glucocorticoids in the medium (Guner et al., 1977) and cloning on homologous feeder layers With the microtitration assay, cultures are usually available for testing_ within 3 weeks of surgery and with an assay taking 10-14 days to perform, a result is available within 4-5 weeks of operation. Currently patients who are to receive chemotherapy for cerebral glioma at the National Hospital do so after completion of radiotherapyusually a minimum of 7-10 weeks after operation. Using a cloning assay where cells are treated in secondary culture with drugs for 3 days and then cloned, it might be difficult to obtain a result within 6-7 weeks of operation.
The acceptance of one parameter rather than another to predict drug sensitivity in vivo will be governed by which value correlates best with the clinical outcome. Preliminary data on a small number of patients suggest that there is an interesting correlation between in vitro data and clinical response (Darling & Thomas, 1981) . In 6 patients with malignant glioma treated with PCB, CCNU and VCR following radiotherapy, three responded. Two of these patients responded in vitro to all 3 drugs and 1 responded to 2 of the 3 drugs. Of the 3 patients who failed to respond clinically, only 1 had a significant response in vitro. This work will be reported fully later.
The majority of samples treated with nitrosourea, VCR or PCB were insensitive. This is also apparent in the clinical treatment of glioma since varying degrees of remission still invariably give way to relapse. There is an indication of low frequency response rate in these studies (15% for VCR, 20% for PCB and 7% for nitrosourea) which, though difficult to evaluate statistically, is of the correct order of magnitude for the anticipated clinical response rate to chemotherapy. Perhaps the most interesting drugs in this survey were the Vinca alkaloids, since they alone produced persistent sensitivity, the sensitive samples falling into a separate and readily distinguishable group. This would perhaps be the best drug to test for clinical correlation. Sensitivity to PCB and nitrosourea was generally poor and showed little evidence of a permanent effect with most cultures. The low levels lg-81 I of sensitivity to PCB may have been due to the lack of generation of the more active metabolites produced in vivo. The nitrosoureas do not normally require metabolic activation. The poor response encountered with them may relate to the observation that high density non-cycling populations are often more sensitive to nitrosourea (Barranco et al., 1973) . Limitations in the microtitration assay makes this difficult to assess but attempts are being made to investigate this with the clonogenic assay.
It is unfortunate that some of the more effective drugs in this series of experiments, e.g. 5-FU, BL
